On August 15, 2024, during a specific object investigation, Zhejiang Jingxin Pharmaceutical (002020.SZ) reported a sales expense of 0.384 billion in the first half of 2024, a 3.63% year-on-year decrease, and a 2.72 percentage point decrease in sales expense ratio. The company has achieved a continuous decrease in sales expenses these years, partly due to the company's emphasis on improving the efficiency of salespeople; on the other hand, it stems from the adjustment of the internal structure of sales expenses, and precise investment in controlling expenses. With the market promotion of Dexinisi, some expenses will inevitably increase, but the company will strive to control the sales expense ratio, hoping to continue to maintain stability or even decrease.